Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1977710 | 0.90 | CNR1 (0.38) | LMNASMN1; SMN2MEN1KMT2AGAA | |
| SCHEMBL1978167 | 0.88 | CNR1 (0.42) | LMNAGAACNR1DAGLABCHE | |
| SCHEMBL1978357 | 0.86 | LMNA (0.39) | LMNASMN1; SMN2MEN1KMT2AGAA | |
| SCHEMBL24687705 | 0.78 | LMNA (0.38) | LMNASMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL18291179 | 0.77 | CNR1 (0.43) | LMNATSHRCNR1DAGLAPFKFB3 | |
| SCHEMBL1978398 | 0.77 | GLI1 (0.43) | LMNASMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL13709164 | 0.77 | GLI1 (0.43) | LMNASMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL1979354 | 0.76 | CNR1 (0.39) | LMNASMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL150243 | 0.74 | SIRT2 (0.32) | — | |
| SCHEMBL9473779 | 0.74 | HSD17B10 (0.42) | LMNASMN1; SMN2MEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927460-B2 | Biocide compositions comprising derivatives of pyroglutamic acid | COGNIS IP MANAGEMENT GMBH (DE) | 2015-01-06 | — | — | US | claimed |
| US-20130102467-A1 | Biocide Compositions Comprising Derivatives of Pyroglutamic Acid | COGNIS IP MANAGEMENT GMBH (DE) | 2013-04-25 | — | — | US | claimed |
| WO-2011072811-A2 | BIOCIDE COMPOSITIONS COMPRISING DERIVATIVES OF PYROGLUTAMIC ACID | COGNIS IP MANAGEMENT GMBH (DE) | 2011-06-23 | — | — | WO | claimed |
| EP-2335480-A1 | Biocide compositions comprising derivatives of pyroglutamic acid | Cognis IP Management GmbH (DE) | 2011-06-22 | — | — | EP | claimed |
| US-20150094206-A1 | Biocide Compositions Comprising Derivatives Of Pyroglutamic Acid | COGNIS IP MAN GMBH (DE) | 2015-04-02 | — | — | US | disclosed |
| US-8927460-B2 | Biocide compositions comprising derivatives of pyroglutamic acid | COGNIS IP MANAGEMENT GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| US-20130102467-A1 | Biocide Compositions Comprising Derivatives of Pyroglutamic Acid | COGNIS IP MANAGEMENT GMBH (DE) | 2013-04-25 | — | — | US | disclosed |
| WO-2011072811-A2 | BIOCIDE COMPOSITIONS COMPRISING DERIVATIVES OF PYROGLUTAMIC ACID | COGNIS IP MANAGEMENT GMBH (DE) | 2011-06-23 | — | — | WO | disclosed |
| EP-2335480-A1 | Biocide compositions comprising derivatives of pyroglutamic acid | Cognis IP Management GmbH (DE) | 2011-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102467-A1 | Biocide Compositions Comprising Derivatives of Pyroglutamic Acid | GLUL, GLO1, PGD | LMNA 2726/4885SMN1; SMN2 4455/4885MEN1 2649/4885 |
| US-20150094206-A1 | Biocide Compositions Comprising Derivatives Of Pyroglutamic Acid | GLUL, GLO1, PGD | LMNA 2726/4885SMN1; SMN2 4455/4885MEN1 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.